



Egyptian Journal of Anaesthesia

ISSN: (Print) 1110-1849 (Online) Journal homepage: https://www.tandfonline.com/loi/teja20

Low dose ketorolac infusion improves postoperative analgesia combined with patient controlled fentanyl analgesia after living donor hepatectomy – Randomized controlled trial

Amr M. Yassen & Gamal El Sayed

To cite this article: Amr M. Yassen & Gamal El Sayed (2012) Low dose ketorolac infusion improves postoperative analgesia combined with patient controlled fentanyl analgesia after living donor hepatectomy – Randomized controlled trial, Egyptian Journal of Anaesthesia, 28:3, 199-204, DOI: <u>10.1016/j.egja.2012.02.010</u>

To link to this article: https://doi.org/10.1016/j.egja.2012.02.010

© 2012 Egyptian Society of Anesthesiologists. Production and hosting by Elsevier B.V.

-	•

6

Published online: 17 May 2019.

ല

Submit your article to this journal \square

Article views: 112



View related articles 🗹



Citing articles: 2 View citing articles



Research Article

Egyptian Society of Anesthesiologists

Egyptian Journal of Anaesthesia

www.elsevier.com/locate/egja www.sciencedirect.com



Low dose ketorolac infusion improves postoperative analgesia combined with patient controlled fentanyl analgesia after living donor hepatectomy – Randomized controlled trial

Amr M. Yassen^{a,*}, Gamal El Sayed^b

^a Department of Anesthesia and Surgical Intensive Care, Mansoura Faculty of Medicine, Egypt ^b Department of Anesthesia and Intensive Care, Zagazig Faculty of Medicine, Egypt

Received 22 February 2012; accepted 27 February 2012 Available online 11 April 2012

KEYWORDS

Ketorolac; Fentanyl; Patient controlled analgesia; Hepatectomy **Abstract** *Background:* Hepatectomy elaborates significant post-operative pain. Opioids represent cornerstone for post-operative analgesia in such cases. This study examined the therapeutic effect and outcome of adding low dose ketorolac tromethamine infusion to PO intravenous patient controlled fentanyl analgesia IV-PCA.

Patients and methods: Sixty right lobe donors were randomized into either fentanyl or ketorolac groups (30 patients each). Patients in both groups received fentanyl (2 μ g/ml) solution in normal saline as IV-PCA with background infusion in a rate adjusted to deliver 0.25 μ g kg h⁻¹ and boluses of 10 ml with a lock-out time of 20 min. They received 15 mg ketorolac IV bolus in ketorolac group and similar placebo injection in the control. Patients in both groups received a continuous intravenous infusion of 240 ml normal saline solution that is either free in the FENT group or containing 60 mg ketorolac in ketorolac group, adjusted to a rate of 0.2 ml kg h⁻¹. Visual analogue score

* Corresponding author. Address: Department of Anesthesia and Surgical Intensive Care, Mansoura Faculty of Medicine, Mansoura, Dakhalia, Egypt. Tel.: +20 1001497044.

E-mail address: amryassen@hotmail.com (A.M. Yassen).

Peer review under responsibility of Egyptian Society of Anesthesiologists.



^{1110-1849 © 2012} Egyptian Society of Anesthesiologists. Production and hosting by Elsevier B.V. Open access under CC BY-NC-ND license. http://dx.doi.org/10.1016/j.egja.2012.02.010

(VAS) and hemodynamic profile were recorded at 1, 6, 12, 24, 36 and 48 h while laboratory results were recorded after 48 h and 7 days post-operatively.

Results: VAS was significantly lower in ketorolac group compared to fentanyl group from 6 to 36 h post-operatively while sedation score was significantly higher in fentanyl group compared to fentanyl–ketorolac group between 12 and 36 h post-operatively. Fentanyl consumption was significantly lower in ketorolac group at 24 (318.7 \pm 66 vs 468.3 \pm 79) and 48 (211.5 \pm 59 vs 369.1 \pm 68) h. Hemodynamic data and laboratory parameters were comparable in both groups. Nausea had a significantly higher incidence in FENT compared to KETR groups while other complications (vomiting and blood loss) were homogenous in both groups.

Conclusion: Adding ketorolac to IV PCA fentanyl improved the analgesic state and reduced the dose of fentanyl used without adding any side effects or risks to donors subjected to right lobe hepatectomy. © 2012 Egyptian Society of Anesthesiologists. Production and hosting by Elsevier B.V.

Open access under CC BY-NC-ND license.

1. Introduction

Post-operative pain constitutes a major problem for patients after major abdominal surgery. Several modalities have been investigated; yet, consensus about an ideal protocol has never been reached. Liver resections mandates grave attention to post-operative analgesia protocol due to both large abdominal incision and the derangements on the drug pharmacokinetics ensued by major hepatic tissue resection. Epidural analgesia is a commonly used modality for post-operative pain management after liver resection [1]. However, the risk of epidural hematoma renders its use in those patients questionable and is often avoided [2].

Cywinski et al. used thoracic patient controlled epidural analgesia (PCEA) in right lobe resection for living liver donation and tumor resection. They found that patients subjected to right lobe liver resection for liver donation experienced significant post-operative pain compared to patients who had resection for malignancy. Additional factors were postulated to explain the predisposition of the right lobe liver donors to augmented post-operative pain perception [3]. Previous investigators demonstrated superiority of the epidurally administered opioids compared to intravenous rout using PCA technique in both [4,5]. Hence, Modifications in the IV PCA technique are required to enhance its activity to match the epidural rout.

Opioid analgesia, especially in high doses has many side effects as nausea, vomiting, pruritus, urinary retention, delayed bowel movement and respiratory depression which limit its use. The association of non-steroidal anti-inflammatory drugs (NSAIDs) with opioid is effective in postoperative analgesia, and can reduce the side effects due to opioid sparing effect [6]. Ketorolac tromethamine is a NSAID with a potent analgesic efficacy. While NSAIDs are always blamed for increasing bleeding tendency [7], lowering the dose of the NSAIDs may be of prime favorable impact on reducing this side effect. So, in this work, we tested the hypothesis that a low dose of ketorolac administered via IV infusion will synergistically add to the analgesic effect of PCA fentanyl without adding morbidity to patients after major hepatectomy. Pain assessed via visual analogue score was the primary outcome parameter in this trial.

2. Patients and methods

After approval of the relevant ethical committee and obtaining informed consent, 60 patients scheduled for right lobe hepatectomy for right lobe liver donation in Mansoura gastroenterol-

ogy surgical centre - liver transplantation program were enrolled in this randomized double-blind controlled trial. Inclusion criteria included patients between 21 and 40 years old and right hepatectomy. Patients receiving non-steroidal anti-inflammatory drugs, anti-platelets or neuro-active or antipsychotic drugs and patients with history of recurrent hyperacidity or gastritis were excluded from the study. All patients were anaesthetized by the same anesthesia team using a standard anesthesia protocol. Anesthesia induction was achieved by intravenous injection of propofol 1 mg kg^{-1} and fentanyl $1 \mu \text{g kg}^{-1}$ and endotracheal intubation was facilitated by rocuronium bromide 0.3 mg kg^{-1} . Anesthesia was maintained by sevoflurane in oxygen/air mixture (40%) and fentanyl infusion 1 µg kg h^{-1} that was discontinued at peritoneal closure. Patients were extubated in the operating theater and transported to the intensive care unit (ICU). Upon admission to the ICU, patients were randomized into one of two groups based on the analgesic regimen using closed envelopes containing a randomly generated sequence of numbers pre allocated to the two groups. Fentanyl group (FENT) represented the control groups and fentanyl + Ketorolac group (KETR) represented the treatment group and each group included 30 patients who were all instructed about the proper use of the PCA pre-operatively and again at admission to the ICU. In both groups, analgesia was achieved via fentanyl using patient controlled intravenous analgesia (PCA). Fentanyl 500 µg were diluted in 250 cc normal saline to have a concentration of 2 µg ml and was attached to PCA pump (LifeCare 4100 PCA II system, by Abbott medical systems, USA). Background infusion was adjusted at a dose of $0.25 \ \mu g \ kg \ h^{-1}$ commenced while the Push up bolus doses were adjusted to give 10 mls of the solution (20 µg) and lock-out interval was adjusted to 20 min. Another solution was prepared containing either 240 ml normal saline (placebo) or 60 mg of ketorolac in 240 ml saline (concentration of 250 µg ml) and the solution was infused continuously in a rate of 0.2 ml kg h $^{-1}$ to deliver a dose of 50 µg kg h $^{-1}$ of ketorolac. Patients in fentanyl group (FENT) received a single injection of 100 ml normal saline (placebo) intravenously over 30 min while in ketorolac group (KETR), patients received a single injection of 15 mg of ketorolac in 100 ml normal saline intravenously over 30 min. All infusions continued for 48 h. Both the patient and the physician assessing the pain score and hemodynamic data were unaware of the infused solutions. Visual analogue score (VAS) was assessed at 1, 6, 12, 24, 36 and 48 h (at rest) using a standard VAS ruler (0-10) and sedation was simultaneously assessed by RAMSY(8) sedation score (6 points score)

by the attending intensive care resident. Nausea and vomiting were assessed on a binary scale (Present/Absent) and were presented as incidence (%). Hemodynamic data were recorded at the same time points with VAS. Laboratory assessment was performed in the morning of the third and seventh post-operative days. Bleeding time was assessed using Duke's technique and blood loss was calculated from the abdominal drains plus any significant soaking of the dressing. Total amount of fentanyl given was recorded at 24 and 48 h. The primary outcome objective of this trial is the 24th hour VAS while secondary objectives included daily fentanyl doses, degree of analgesia, hemodynamic profile, laboratory profiles and complications.

2.1. Statistical analysis

The primary outcome objective in this trial was VAS. For sample size determination, the 24th hour value was used for effect size. A priori power study was performed to detect an effect size of 20% and alpha error or 0.05% to acquire 90% power. 26 cases per group were required to achieve the designated power yet, 30 patients were enrolled in every group for compensating for probable withdrawals and disqualifications. Continuous data were tested for normality using kolmogrove-smirnove test and all exhibited normal distribution and were presented as mean \pm SD. Differences between groups were tested using two-tailed independent sample t test (equal variance assumed). Interval data and total fentanyl doses were tested for significant difference between groups using Mann-Whitney U test. Incidence of nausea and vomiting was compared using Chi square. Statistical significance was assumed when P is less than or equal to 0.05 and analysis was performed using Statistical package for social sciences (SPSS) ver 14.USA.

3. Results

The study recruited 60 patients who were randomized into either fentanyl or fentanyl + ketorolac groups. 30 patients were enrolled in each group. Out of them 29 patients completed the protocol in FENT group while 1 patient was excluded during the study period due to revision operation (patient 8). In KETR group, 28 patients completed the protocol while one case was excluded due to surgical revision and another case for protocol violation (Unblinding) (patient 32) (Fig. 1). Neither patient characteristics nor operative data showed any significant differences between the studied groups (Table 1). Day three hemoglobin, ICU blood loss and ICU stay were homogenous among both groups (Table 1). Table 2 demonstrates MAP, HR and RR for the studied groups and showed no significant differences in these parameters among patients in both groups. Visual analogue score was significantly lower in KETR group compared to similar values in FENT group starting from 6 h reading until 36 h readings while sedation score was significantly higher in the FENT group compared to the KETR group from 12 to 36 h post-operatively (Fig. 2). Meanwhile, the Daily doses of fentanyl were significantly lower in KETR group compared to FENT group at 24 h (318.7 \pm 66 µg vs 468.3 \pm 79 µg, P = 0.013, CI = (11.50–92.13) and 48 h (211.5 ± 59 µg vs $369.1 \pm 68 \,\mu\text{g}, P = 0.001, \text{CI} = (70.45 - 112.56) \text{ (Fig. 3). Out-}$ come parameters included liver functions, renal functions and coagulation profile. Neither of these outcome parameters




Figure 1 CONSORT chart.

demonstrated significant difference between both groups both at 3rd and 7th PO days (Table 3). Nausea was significantly more frequent in the FENT group compared to KETR group (58.62 vs 21.42, P = 0.021) while vomiting, and blood loss did not differ significantly among the studies groups (Table 4).

4. Discussion

This trial evaluated the analgesic efficacy of adding low dose of ketorolac tromethamine continuous intravenous infusion to IV PCA fentanyl after right lobe donor hepatectomy and found that the addition of ketorolac to IV PCA fantanyl achieved better analgesia, better patients alertness and reduced the incidence of nausea in this sensitive patient group without adding any morbidity.

Intravenous patient controlled analgesia give good analgesia and patient satisfaction by allowing the patients to control their pain [9,10]. In this study, patients receiving both IV PCA fentanyl and IV infusion of Ketorolac experienced less pain expressed as a significantly lower visual analogue score compared to patients receiving IV PCA fentanyl only from 6 to 36 h postoperatively. IV-PCA using both opioids and NSAIDs is a common method for acute post-operative pain management. The synergism between NSAIDs working primarily via modulation of arachidonic acid cascade at peripheral sites with opioids that act mainly centrally on specific receptors is effective in different types of surgery [11,12]. Na et al concluded that IV-PCA with fentanyl and ketorolac provides satisfactory and safe posto-perative analgesia after craniotomy [13].

In our trial, we investigated right lobe liver donors who share common characteristic features that influence drug phar-

Table 1	Patients	characteristics:	Data	are in mean	\pm SD,	number	(range)	or ratio.
---------	----------	------------------	------	-------------	-----------	--------	---------	-----------

	FENT group	KETR group	P value	
Age (years)	28.24 ± 5.2	30.18 ± 4.9	0.166	
Sex (M/F)	24/5	26/2	0.348	
BMI	21.2 ± 2.1	22.3 ± 1.9	0.094	
Operative duration (min)	273.6 ± 56	301.7 ± 69	0.231	
Intraoperative fentanyl (Ug)	463 ± 105	415 ± 97	0.524	
ICU stay number (Range)	2(2-3)	2(2-3)	0.92	
Platelets	303.3 ± 56.3	295.5 ± 45.9	0.073	
Admission Hg	12.45 ± 1.1	12.3 ± 1.3	0.064	
Day 3 Hg	11.8 ± 1.1	11.4 ± 1.2	0.311	
IO blood product transfusion	0	0	-	
Remaining liver volume (%)	37.4 ± 3.1	36.3 ± 2.9	0.427	

Table 2	Table 2 Hemodynamic data of FENT group ($n = 29$) and KETR group ($n = 28$): Data are in mean \pm SD.								
	Heart rate		Р	Mean arterial pressure		Р	Respiratory rate		Р
	FENT group	KETR group		FENT group	KETR group		FENT group	KETR group	
1 h PO	87.3 ± 4.5	85.5 ± 6.8	0.214	85.5 ± 3.8	86.3 ± 2.8	0.344	20 ± 3.1	21 ± 3.3	0.748
6 h PO	85.3 ± 4.2	82.3 ± 6.1	0.425	90.8 ± 4.8	$93.3~\pm~5.6$	0.056	19.2 ± 2.5	$20.2~\pm~1.0$	0.453
12 PO	81.7 ± 4.1	$80.3~\pm~3.7$	0.061	89.8 ± 5.2	$88.7~\pm~5.3$	0.741	17.3 ± 1.9	19.0 ± 2.5	0.081
24 h PO	$78.8~\pm~4.7$	$79.2~\pm~5.4$	0.121	82.5 ± 5.7	$86.2~\pm~5.5$	0.455	15.3 ± 1.6	$14.8~\pm~1.9$	0.132
36 h PO	$79.5~\pm~5.3$	$80.3~\pm~4.5$	0.072	$88.2~\pm~4.8$	$87.2~\pm~5.0$	0.059	14.3 ± 1	14.2 ± 1.2	0.063
48 h PO	78.5 ± 3.9	$79.0~\pm~3.5$	0.278	$79.8~\pm~1.5$	$82.2~\pm~6.1$	0.521	$14.0~\pm~1.8$	13.5 ± 1.5	0.547
DO D									

PO = Post-operative.




Figure 2 Visual analogue score and sedation score for the studied groups. *Significant compared to Fentanyl group.

macokinetics in general. First, around 60–65% of their liver is usually resected reducing their metabolic capacity of the liver especially for drugs which are primarily metabolized through the liver like Ketorolac [14]. Second, those patients almost always receive no blood product transfusion for fear of transfusion acquired infections, hence, blood loss is always replaced by fluids reducing the circulating quantity of plasma proteins and diluting the already existing amount. Drugs that are extensively pound to plasma proteins like ketorolac will subsequently have a more free active percentage of the drug in the circulation [14]. These two elements justified the use of a lower dose of ketorolac in this patient category compared to the standard dosage recommended in other post-operative settings




Figure 3 Fentanyl used in the study groups during the study period.^{*}Significant compared to Fentanyl group.

[15] Our findings supported these assumptions since an appreciably low dose of ketorolac infusion (50 µg kg h⁻¹) could achieve the desired analgesic target. Both groups exhibited a difference between them after 6 h from starting the infusion, a time that was required to build up a sufficient trough level of ketorolac in the plasma after a reduced bolus dose of 15 mg given initially to this group that could not initiate a statistically significant difference with the control group in this early phase with maximum pain. Meanwhile, at 48 h, patients in both groups had a satisfactory analgesia. A finding that points mainly to the build up of a sufficient analgesic barrier by fentanyl alone fortified by the chronologically induced reduction of pain intensity after 48 h from surgery.

	FENT group	KETR group	Difference (95% CI)
Day 3 Lab. results			
S. Bilirubin	2.05 ± 0.76	1.85 ± 0.50	0.20 (-0.63 to 1.03)
ALT	187.8 ± 85.92	173.7 ± 32.8	14.17 (-69.49 to 97.83)
PC	66.0 ± 7.9	68.5 ± 8.1	-2.5 (-12.77 to 7.77)
INR	1.6 ± 0.37	1.6 ± 0.23	-0.02 (-0.41 to 0.38)
Bleeding time	3.2 ± 1.4	3.5 ± 1.9	-0.30 (-1.10 to 0.96)
Factor V	57.0 ± 7.3	61.2 ± 9.6	-4.20 (-15.10 to 1.23)
aPTT	46.5 ± 7.0	47.5 ± 6.2	-1.0 (-9.54 to 7.44)
S. Createnine	1.0 ± 0.14	0.95 ± 0.16	0.05 (-0.15 to 0.25)
Blood urea	28.0 ± 3.58	26.5 ± 5.43	1.50 (-4.42 to 7.24)
Day 7 Lab. results			
S. Bilirubin	1.17 ± 0.12	1.7 ± 0.23	0.00 (-0.23 to 0.24)
ALT	69.7 ± 32.4	58.2 ± 26.8	11.5 (-21.4 to 16.8)
PC	83.5 ± 6.7	85.4 ± 6.0	-1.83 (-9.9 to 6.33)
INR	1.17 ± 0.08	1.06 ± 0.08	-0.01 (-0.11 to 0.12)
Bleeding time	2.8 ± 1.0	3.0 ± 1.2	-0.20 (-0.970 to 0.78)
Factor V	91.0 ± 3.5	90.8 ± 2.9	0.16 (-3.99 to 4.33)
aPTT	42.8 ± 10.2	44.3 ± 8.9	-1.4 (-7.63 to 6.96)
S. Createnine	0.87 ± 0.18	0.71 ± 0.37	0.16 (-0.22 to 0.53)
Blood urea	20.83 ± 2.48	23.33 ± 4.23	-2.50 (-6.95 to 1.96)

Table 3 Outcome parameters (liver functions, coagulation profile, renal functions and blood loss)data of FENT group (n = 29) and KETR group (n = 28) at post-operative day 3 and day 7: Data are in mean \pm SD.

ALT = alanine aminotransferase, PC = prothrombine concentration, INR = international normalization ratio and aPTT = activated partial thromboplastine time.

Table 4	Complications of FENT group $(n = 29)$ and KET	R
group (n	= 28).	

	FENT	KETR	P value
Nausea (%)	58.62	21.42*	0.021
Vomiting (%)	7.14	10.34	0.415
Blood loss (ml)	301.7 ± 26.4	268.3 ± 0.24	0.113

* P < 0.05 compared to the control group.

Munro et al, in their trial, were in agreement with our findings regarding the synergistic effects of adding sub-standard dose of ketorolac to opioid analgesic were they recorded a lower pain score in the ketorolac treatment group and also, lower opioid consumption (20%) in both post-operative day 1 and day 2 compared to opioid only control group [16]. Similar results was achieved by Kim and his collogues using remifentanil and ketorolac [17].

In this work, we assessed sedation in this trial using the 6 points Ramsey sedation score [8]. Patients in KETR group exhibited better (lower) sedation score compared to patients in FENT group between 12 and 36 h post-operatively. The significantly lower overall daily dose of fentanyl administered in the KETR group compared to the FENT group by 31.9% in the first 24 h and by 42.7 in the second 24 h could justify the higher sedation score in the FENT group. Previous investigators had similar results with the addition of ketorolac to their post-operative opioid based analgesia. (REF KIM) The lack of significant difference in the sedation score between both groups at the end of the study (48 h) is attributed to the very low sedation score achieved in both of them with patients requiring less fantanyl in both groups compared to the first 24.

NSAIDs are accused by increasing blood loss duo to inhibition of platelet aggregation [18]. Yet, the results are

conflicting among different subsets of NSAIDs [19]. Previous investigators reported an increase in the bleeding tendency in their trials using ketorolac [7,20]. Yet, in these two trials, a different population (pediatric) was used, the type of operation (tonsillectomy) where the incidence of bleeding is increased by 3.5 times in ENT surgery compared to other surgical sites [21] and the dose of ketorolac given in both studies (1 mg kg) were the complications of ketorolac were previously demonstrated to be dose-dependent [22] may have participate in these results that are contradictory to our findings in this trial were the addition of ketorolac to IV PCA fentanyl did not induce any significant differences from the control group in bleeding time, transfusion requirements or blood loss. Liver resection results in decrease in the concentration of clothing factors due to transient insufficiency of the remaining liver to synthesize new factors, factor consumption and operative fibrinolysis [23,24]. However, this effect is time dependant and may not be effective during the first 24-48 h post-operatively especially with donor hepatectomy due to the supreme quality of the donor liver documented through the extensive pre-transplant work up in our center including liver biopsy.

The incidence of nausea in our trial was significantly lower in the kETR group compared to the control group. These results were in agreement with previous work on abdominal surgery with reported reduction of the incidence of nausea in ketorolac treated patients [12]. Previous studies reported an anti-emmitc effect of ketorolac in different post-operative settings [25,26].

One of the study limitations was the restriction of the cohort to a limited age group (21–40) which is the age for acceptance for right lobe liver donation in our program, hence, we cannot recommend extrapolation of our findings to different age groups. Also, the excellent quality of the donor livers may have played a major role in the results of our study that may not be safely achieved if applied to patients with diseased liver subjected to major hepatectomy. We could conclude that low dose iv infusion Ketorolac tromethamine augmented the post-operative analgesic effect of IV PCA fentanyl without any added morbidity to patients subjected to right lobe liver hepatectomy for liver donation.

References

- Matot I, Scheinin O, Eid A, Jurim O. Epidural anesthesia and analgesia in liver resection. Anesth Analg 2002;95:1179–81.
- [2] Roy j, Massicotte L, Sassine M, Seal R, et al. Comparison of intrathecal morphine/fentanil and patient-controlled analgesia with patient-controlled analgesia alone for analgesia after liver resection. Anesth Analg 2006;103:990–4.
- [3] Cywinski JB, Parker BM, Xu M, Irefin SA. A comparison of postoperative pain control in patients after right lobe donorhepatectomy and major hepatic resection for tumor. Anesth Analg 2004;99:1747–52.
- [4] Lee S, Kim K, Cheong S, Kim S, et al. Comparison of the effect of epidural patient-controlled analgesia with intravenous patient-controlled analgesia on pain control after posterior lumbar instrumented fusion. J Korean Neurosurg Soc 2011;50:205–8.
- [5] Cluade M, Yvan P, Gills B, Christine P, et al. Comparison of intravenous or epidural patient-controlled analgesia in the elderly after major abdominal surgery. Anesthesiology 2000;92:433–44.
- [6] Gillies GW, Kenny GN, Bullingham RE, Mc Ardle CS. The morphine sparing effect of Ketorolac tromethamine a study of a new potential nonsteroidal anti-inflammatory agent after abdominal surgery. Anaesthesia 1987;42:727–31.
- [7] Rusy LM, Houck CS, Sullivan LJ, Ohlms LA, Jones DT, McGill TJ, Berde CB. A double-blind evaluation of ketorolac tromethamine versus acetaminophen in pediatric tonsillectomy: analgesia and bleeding. Anesth Analg 1995;80:226–9.
- [8] Ramsay MA, Savege TM, Simpson BR, Goodwin R. Controlled sedation with alphaxalone-alphadolone. Br Med J 1974;2:656–9.
- [9] Walder B, Schafer M, Henzi I, Tramèr MR. Efficacy and safety of patient-controlled opioid analgesia for acute postoperative pain. A quantitative systematic review. Acta Anaesth Scand 2001;45:795–804.
- [10] Macintyre PE. Safety and efficacy of patient-controlled analgesia. Br J Anaesth 2001;87:36–46.
- [11] Verrassi G, Marinangeli F, Agro F, Aloe LA. Double-Blind evaluation of propacetamol versus Ketorolac in combination with patient-controlled analgesia Morphine: analgesic efficacy and tolerability after gynecologic surgery. Anesth Analg 1999;88:611–6.
- [12] Parker RK, Holtmann B, Smith I, White PF. Use of ketorolac after lower abdominal surgery. Effect on analgesic requirement and surgical outcome. Anaesthesiology 1994;80(1):6–12.

- [13] Na H, An S, Park H, Lim Y. Intravenous patient controlled analgesia to manage the postoperative pain in patients undergoing craniotomy. Korean J Anesthesiol 2011;60:30–5.
- [14] Mroszczak EJ, Jung D, Yee J, Bynum L, Sevelius H, Massey I. Ketorolac tromethamine pharmacokinetics and metabolism after intravenous, intramascular and oral administration in humans and animals. Pharmacotherapy 1990;10(6):33–9.
- [15] Kim SY, Kim EM, Nam KH, Chang DJ, Nam SH, Kim KJ. Postoperative intravenous patient-controlled analgesia in thyroid surgery: comparison of fentanyl and ondansetron regimens with and without the nonsteriodal anti-inflammatory drug ketorolac. Thyroid. 2008 Dec;18(12):1285–90.
- [16] Munro H, Walton S, Malviya S, Merkel S. Low-dose Ketorolac improves analgesia and reduces morphine requirements following posterior spinal fusion in adolescents. CAN J Anesth 2002;49:461–6.
- [17] Kim J, Ha M, Jung S, Song N. The efficiency of IV PCA with remifentanil and ketorolac after laparoscopic-assisted vaginal hysterectomy. Korean J Anesthesiol 2011;61:42–9.
- [18] Souter AH. Controversies in the perioperative use of nonsteriodal anti-inflamatory drugs. Anesth Analg 1994;79:1178–90.
- [19] Gonzalez EL, Patrignani P, Tacconelli S, Rodriguez LA. Variability among nonsteriodal antiinflamatory drugs in risk of upper gastrointestinal bleeding. Arthritis Rheum 2010;62(6):1592–601.
- [20] Gunter JB, Varughese AM, Harrington JF, Wittkugel EP, Pantakar SS, Matar MM, Lowe EE. Recovery and complications after tolsillectomy in children: a comparison of ketorolac and morophine. Anesth Analg 1995;81:1136–41.
- [21] Forrest JB, Camu F, Greer IA, Kehlet H, Abdulla M, Bonnet F, et al. Ketorolac, diclofenac and ketoprofen are equally safe for pain relief after major surgery. Br J Anaesth 2002;88(2):227–33.
- [22] Reuben SS, Connelly NR, Lurie S, Klatt M, Gibson CS. Doseresponse of ketorolac as an adjunct to patient controlled analgesia morphine in patients after spinal fusion surgery. Anesth Analg 1998;87:98–102.
- [23] Borromeo CJ, Stix MS, Lally A, Pomfret EA. Epidural catheter and increased prothrombin time after right lobe hepatectomy for living donor transplantation. Anesth Analg 2000;91:1139–41.
- [24] Weinberg L, Scurrah N, Gunning K, McNicol L. Postoperative changes in prothrombin time following hepatic resection: implications for perioperative analgesia. Anaesth Intensive Care 2006;34(4):438–43.
- [25] Thagaard KS, Jensen HH, Raeder J. Analgesic and antiemetic effect of ketorolac vs. betamethasone or dexamethasone after ambulatory surgery. Acta Anaesthesiol Scand 2007;51(3):271–7.
- [26] Shende D, Das K. Comparative effects of intravenous ketorolac and pethidine on perioperative analgesia and postoperative nausea and vomiting (PONV) for paediatric strabismus surgery. Acta Anaesthesiol Scand 1999;43(3):265–9.